<DOC>
	<DOCNO>NCT03070327</DOCNO>
	<brief_summary>The purpose phase I clinical trial test safety CAR T cell patient myeloma plasma cell leukemia .</brief_summary>
	<brief_title>BCMA Targeted CAR T Cells Treatment Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients must histologically confirm MM PCL MSKCC pathologist , MM cell express BCMA , previously treat 2+ prior line therapy include IMiD PI , either refractory , persistent , progressive disease Age ≥ 18 year age Creatinine ≤2.0 mg/dL , direct bilirubin ≤2.0 mg/dL , AST ALT ≤3.0x upper limit normal ( ULN ) Adequate pulmonary function assess ≥92 % oxygen saturation room air pulse oximetry . Karnofsky performance status &lt; 70 Pregnant lactate woman . Women men childbearing age use effective contraception study continue 1 year treatment finish Impaired cardiac function ( LVEF &lt; 40 % ) assess ECHO MUGA scan Patients follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Myocardial infarction ≤6 month prior enrollment History clinically significant ventricular arrhythmia unexplained syncope , believe vasovagal nature due dehydration History severe nonischemic cardiomyopathy Patients HIV active hepatitis B hepatitis C infection ineligible Patients concurrent active malignancy define malignancy require therapy expectant observation hormonal therapy , exception squamous basal cell carcinoma skin Patients prior allogeneic transplant ARE eligible UNLESS previously currently experience GvHD required systemic steroid systemic lymphotoxic therapy Patients systemic steroid ( except solely adrenal replacement ) within two week collection Active autoimmune disease include connective tissue disease , uveitis , sarcoidosis , inflammatory bowel disease , multiple sclerosis , history severe ( judged principal investigator ) autoimmune disease require prolonged immunosuppressive therapy Prior treatment gene modify T cell Prior active CNS involvement myeloma ( eg leptomeningial disease ) . Screening , example , lumbar puncture , require suspicious symptom radiographic finding present Preexisting ( active severe ) neurologic disorder ( e.g . preexist seizure disorder ) Active uncontrolled acute infection Any issue , opinion treat physician , would make patient ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>B-cell Maturation Antigen ( BCMA )</keyword>
	<keyword>Targeted EGFRt/BCMA-41BBz</keyword>
	<keyword>Chimeric antigen receptor ( CAR )</keyword>
	<keyword>17-025</keyword>
</DOC>